BACKGROUND: The TBscore, based on simple signs and symptoms, was introduced to predict unsuccessful outcome in tuberculosis patients on treatment. A recent inter-observer variation study showed profound variation in some variables. Further, some variables depend on a physician assessing them, making the score less applicable. The aim of the present study was to simplify the TBscore. METHODS: Inter-observer variation assessment and exploratory factor analysis were combined to develop a simplified score, the TBscore II. To validate TBscore II we assessed the association between start score and failure (i.e. death or treatment failure), responsiveness using Cohen's effect size, and the relationship between severity class at treatment start and a decrease < 25% in score from the start until the end of the second treatment month and subsequent mortality. RESULTS: We analyzed data from 1070 Guinean (2003-2012) and 432 Ethiopian (2007-2012) pulmonary tuberculosis patients. For the refined score, items with less than substantial agreement (κ ≤ 0.6) and/or not associated with the underlying constructs were excluded. Items kept were: cough, dyspnea, chest pain, anemia, body mass index (BMI) < 18 kg/m(2), BMI < 16 kg/m(2), mid upper arm circumference (MUAC) < 220 mm, and MUAC < 200 mm. The effect sizes for the change between the start of treatment and the 2-month follow-up were 0.51 in Guinea-Bissau and 0.68 in Ethiopia, and for the change between the start of treatment and the end of treatment were 0.68 in Guinea-Bissau and 0.74 in Ethiopia. Severity class placement at treatment start predicted failure (p < 0.001 Guinea-Bissau, p = 0.208 Ethiopia). Inability to decrease at least 25% in score was associated with a higher failure rate during the remaining 4 months of treatment (p = 0.063 Guinea-Bissau, p = 0.008 Ethiopia). CONCLUSION: The TBscore II could be a useful monitoring tool, aiding triage at the beginning of treatment and during treatment.
BACKGROUND: The TBscore, based on simple signs and symptoms, was introduced to predict unsuccessful outcome in tuberculosispatients on treatment. A recent inter-observer variation study showed profound variation in some variables. Further, some variables depend on a physician assessing them, making the score less applicable. The aim of the present study was to simplify the TBscore. METHODS: Inter-observer variation assessment and exploratory factor analysis were combined to develop a simplified score, the TBscore II. To validate TBscore II we assessed the association between start score and failure (i.e. death or treatment failure), responsiveness using Cohen's effect size, and the relationship between severity class at treatment start and a decrease < 25% in score from the start until the end of the second treatment month and subsequent mortality. RESULTS: We analyzed data from 1070 Guinean (2003-2012) and 432 Ethiopian (2007-2012) pulmonary tuberculosispatients. For the refined score, items with less than substantial agreement (κ ≤ 0.6) and/or not associated with the underlying constructs were excluded. Items kept were: cough, dyspnea, chest pain, anemia, body mass index (BMI) < 18 kg/m(2), BMI < 16 kg/m(2), mid upper arm circumference (MUAC) < 220 mm, and MUAC < 200 mm. The effect sizes for the change between the start of treatment and the 2-month follow-up were 0.51 in Guinea-Bissau and 0.68 in Ethiopia, and for the change between the start of treatment and the end of treatment were 0.68 in Guinea-Bissau and 0.74 in Ethiopia. Severity class placement at treatment start predicted failure (p < 0.001 Guinea-Bissau, p = 0.208 Ethiopia). Inability to decrease at least 25% in score was associated with a higher failure rate during the remaining 4 months of treatment (p = 0.063 Guinea-Bissau, p = 0.008 Ethiopia). CONCLUSION: The TBscore II could be a useful monitoring tool, aiding triage at the beginning of treatment and during treatment.
Authors: Jan Heyckendorf; Sophia B Georghiou; Nicole Frahm; Norbert Heinrich; Irina Kontsevaya; Maja Reimann; David Holtzman; Marjorie Imperial; Daniela M Cirillo; Stephen H Gillespie; Morten Ruhwald Journal: Clin Microbiol Rev Date: 2022-03-21 Impact factor: 50.129
Authors: Lauren S Peetluk; Felipe M Ridolfi; Peter F Rebeiro; Dandan Liu; Valeria C Rolla; Timothy R Sterling Journal: BMJ Open Date: 2021-03-02 Impact factor: 2.692
Authors: T T Balcha; S Skogmar; E Sturegård; T Schön; N Winqvist; A Reepalu; Z H Jemal; G Tibesso; J Björk; P Björkman Journal: Open Forum Infect Dis Date: 2014-10-10 Impact factor: 3.835
Authors: Omara Dogar; Deepa Barua; Melanie Boeckmann; Helen Elsey; Razia Fatima; Rhian Gabe; Rumana Huque; Ada Keding; Amina Khan; Daniel Kotz; Eva Kralikova; James N Newell; Iveta Nohavova; Steve Parrott; Anne Readshaw; Lottie Renwick; Aziz Sheikh; Kamran Siddiqi Journal: Addiction Date: 2018-04-20 Impact factor: 6.526
Authors: Lina Davies Forsman; Katarina Niward; Yi Hu; Rongrong Zheng; Xubin Zheng; Ran Ke; Weiping Cai; Chao Hong; Yang Li; Yazhou Gao; Jim Werngren; Jakob Paues; Johanna Kuhlin; Ulrika S H Simonsson; Erik Eliasson; Jan-Willem Alffenaar; Mikael Mansjö; Sven Hoffner; Biao Xu; Thomas Schön; Judith Bruchfeld Journal: BMJ Open Date: 2018-10-04 Impact factor: 2.692
Authors: Carolin T Turner; Rishi K Gupta; Evdokia Tsaliki; Jennifer K Roe; Prasenjit Mondal; Georgina R Nyawo; Zaida Palmer; Robert F Miller; Byron Wp Reeve; Grant Theron; Mahdad Noursadeghi Journal: Lancet Respir Med Date: 2020-03-13 Impact factor: 30.700